Published in Cancer Weekly, September 9th, 2003
Two identical studies, called IMPACT I and II, are being conducted simultaneously by gynecologic cancer specialists at U.Va. and the University of California, Los Angeles (UCLA). The pivotal, confirmatory Phase III trial involves a new antibody called OvaRex (Unither Pharmaceuticals) that is thought to work by stimulating the body's immune system to recognize...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.